Introduction of Viral Inactivation to Ensure Safety from The Virus

Inactivation or removal of viral using techniques such as pH, disinfectants, heat treatment, detergents ultraviolet radiation, ionizing radiation, desiccation, antiseptics and organic solvents in which virus may present in the final product but in non-infective form is called viral inactivation. The other methods of viral inactivation include ultraviolet-C (UVC) light which is low-dose radiation at a wavelength of 254 nm. Further, UVC is an effective method for non-enveloped viruses and high temperature short-time (HTST) treatment for inactivation. Using virus inactivation method during production can alleviate some concerns about potentially infectious, adventitious, or endogenous agents. Viral inactivation is used widely in the blood plasma industry, vaccines & therapeutics, tissues & tissue products, and stem cell products. The viral inactivation method is also being used by academic research institutes, pharmaceutical & biotechnology companies and contract research organizations (CRO). Viral Inactivation is a part of viral clearance that is mandatory for any drug development which makes viral inactivation a useful part of the drug development process.

Browse the full report of Viral Inactivation Market by Product Type (Kits and Reagents, Systems, and Services), by Application (Vaccines and Therapeutics, Blood and Blood Products, Stem Cell Products, Tissue and Tissue Products, and Others), by End-User (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations (CROs) and Others) –  Industry Size, Share, Trends, Growth and Forecasts, 2019–2025 at https://www.omrglobal.com/industry-reports/viral-inactivation-market/

The global viral inactivation market growth is influenced by the rising number of new drug launches, fast growth in pharmaceutical & biotechnology industries, strong R&D investments in the life sciences industry and growing government support for pharmaceutical & biotechnology industries. The concern about bioterrorism and the rapid transport of viral agents by the traveling public is working as a motivation behind the increased development and R&D in viral inactivation field.

Increased demand for advanced healthcare infrastructure and life science research in Asia-Pacific is expected to lead the global viral inactivation market. Key players in the viral inactivation market include WuXi PharmaTech (Cayman) Inc. (China), Rad Source Technologies (U.S.), Clean Cells (France), Charles River Laboratories International, Inc. (U.S.), Viral Inactivated Plasma Systems SA (Switzerland),  Merck group (Germany), Parker Hannifin (U.S.), Sartorius AG (Germany), SGS S.A. (Switzerland), Texcell, Inc. (France), and Danaher Corp (U.S.).

Current Market Trends Covered in the market report:

• Increased investment for the development of the life sciences segment driving the viral inactivation market.
• UV-C new viral inactivation technology that is simple to integrate into a purification process and has less critical process parameters.
• A lab-scale prototype viral inactivation system for the continuous process was designed, built, and characterized to be used for viral inactivation.
• Cadence virus inactivation system is recently introduced for the commercial use which performs low pH virus inactivation in a continuous incoming elution stream with minimum operator involvement.

The Report Global Viral Inactivation Market Segmentation

By Product Type

• Kits & Reagents
• Systems
• Services

By Application

• Vaccines and Therapeutics
• Blood and Blood Products
• Stem Cell Products
• Tissue and Tissue Products
• Others (Cellular and Gene Therapy Products)

By End-User

• Pharmaceutical and Biopharmaceutical Companies
• Contract Research Organizations
• Others (Research Institutes)

By Region

North America

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America